October 09, 2019
OSLO, Norway, Oct. 9, 2019 /PRNewswire/ -- Targovax ASA (OSE: TRVX), announces that clinical data on the company's lead product candidate ONCOS-102, a genetically modified oncolytic adenovirus which has been engineered to selectively infect and replicate in cancer cells, will be presented...
Source URL: https://www.prnewswire.com:443/news-releases/targovax-selected-for-oral-presentation-at-society-for-immunotherapy-of-cancer-sitc-2019-annual-meeting-300934520.html
|
